Trial document

drksid header

DRKS-ID: DRKS00016416

Trial Description

start of 1:1-Block title

Title

Prospective evaluation of detection of circulating tumor DNA (ctDNA) to predict recurrence after definitive therapy of localized stage lung cancer (PREDICT)

end of 1:1-Block title

start of 1:1-Block acronym

Trial Acronym

PREDICT

end of 1:1-Block acronym

start of 1:1-Block url

URL of the Trial

[---]*

end of 1:1-Block url

start of 1:1-Block public summary

Brief Summary in Lay Language

[---]*

end of 1:1-Block public summary

start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

Lung cancer patients treated with curative intent with suffer a recurrence in 30 – 80% of cases depending on stage and treatment. At recurrence, curative treatment is generally not possible. Therefore, patients are offered adjuvant therapy aimed at reducing the risk of recurrence. Adjuvant therapy consists of chemotherapy or more recently immuno-oncological treatment. With current diagnostic methods, the individual risk of recurrence cannot be estimated in detail. Therefore, all patients receive adjuvant treatment, even if they might be already cured by the definitive therapy and would not have a recurrence anyway. If these patients, who will not have a recurrence, could be identified prior to adjuvant therapy with a sufficiently accurate diagnostic test, these patients would not require adjuvant therapy. This would reduce morbidity, mortality, and cost. High-sensitivity measurement of pre- and post-therapeutic circulating tumor-DNA (ctDNA) in peripheral blood could provide such a test.
The planned PREDICT study will prospectively non-interventionelly test, whether the measurement of ctDNA is feasible in routine clinical practice, and whether ctDNA accurately predicts the risk of recurrence and survival in a lung cancer population treated with curative intent.

end of 1:1-Block scientific synopsis

start of 1:1-Block forwarded Data

Do you plan to share individual participant data with other researchers?

[---]*

end of 1:1-Block forwarded Data

start of 1:1-Block forwarded Data Content

Description IPD sharing plan:

[---]*

end of 1:1-Block forwarded Data Content

start of 1:1-Block organizational data

Organizational Data

DRKS-ID: DRKS00016416
Date of Registration in DRKS: 2019/04/08
Date of Registration in Partner Registry or other Primary Registry: [---]*
Investigator Sponsored/Initiated Trial (IST/IIT): yes
Ethics Approval/Approval of the Ethics Committee: Approved
(leading) Ethics Committee No.: F-2019-002, Ethik-Kommission bei der Landesärztekammer Baden-Württemberg

end of 1:1-Block organizational data

start of 1:n-Block secondary IDs

Secondary IDs

[---]*

end of 1:n-Block secondary IDs

start of 1:N-Block indications

Health Condition or Problem studied

Free text: lung cancer nsclc and sclc

end of 1:N-Block indications

start of 1:N-Block interventions

Interventions/Observational Groups

Arm 1: Based on the ctDNA results, the study population will be analyzed in 3 arms:
1. ctDNA pre-therapeutically detectable and post-therapeutically not detectable.
Arm 2: 2. ctDNA pre-therapeutically detectable und post-therapeutically detectable
Arm 3: 3. ctDNA pre-therapeutically not detectable

end of 1:N-Block interventions

start of 1:1-Block design

Characteristics

Study Type: Non-interventional
Study Type Non-Interventional: Other
Allocation: Other
Blinding: Blinded
Who is blinded: patient/subject, investigator/therapist, caregiver, data analyst
Control: Other
Purpose: Prognosis
Assignment: Other
Phase: N/A
Off-label Drug use: N/A

end of 1:1-Block design

start of 1:1-Block primary endpoint

Primary Outcome

Recurence-free survival at 1, 2, 3, 5 years post-therapeutically.

end of 1:1-Block primary endpoint

start of 1:1-Block secondary endpoint

Secondary Outcome

Overall-survival

end of 1:1-Block secondary endpoint

start of 1:n-Block recruitment countries

Countries of Recruitment

DE: Germany

end of 1:n-Block recruitment countries

start of 1:n-Block recruitment locations

Locations of Recruitment

Medical Center Klinik für Kardiologie und Pneumologie, Klinikum Esslingen, Esslingen am Neckar

end of 1:n-Block recruitment locations

start of 1:1-Block recruitment

Recruitment

Planned/Actual: Actual
(Anticipated or Actual) Date of First Enrollment: 2019/03/19
Target Sample Size: 180
Monocenter/Multicenter trial: Monocenter trial
National/International: National

end of 1:1-Block recruitment

start of 1:1-Block inclusion criteria

Inclusion Criteria

Gender: Both, male and female
Minimum Age: 18 Years
Maximum Age: no maximum age

end of 1:1-Block inclusion criteria

start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

Patients with NSCLC stage I-IVA with planned curative therapy. SCLC stage I-IIIC with planned curative therapy.

end of 1:1-Block inclusion criteria add

start of 1:1-Block exclusion criteria

Exclusion Criteria

None

end of 1:1-Block exclusion criteria

start of 1:n-Block addresses

Addresses

Primary Sponsor
start of 1:1-Block address primary-sponsor
- Klinik für Kardiologie und Pneumologie, Klinikum Esslingen
- 73730 Esslingen
- Germany
end of 1:1-Block address primary-sponsor

start of 1:1-Block address contact primary-sponsor
- Telephone: [---]*
- Fax: [---]*
- E-mail: [---]*
- URL: [---]*
end of 1:1-Block address contact primary-sponsor
Collaborator, Other Address
start of 1:1-Block address other
- Institut für Pathologie, Uniklinik Heidelberg
- Mr. Prof. Dr. med. Albrecht Stenzinger
- Germany
end of 1:1-Block address other

start of 1:1-Block address contact other
- Telephone: [---]*
- Fax: [---]*
- E-mail: [---]*
- URL: [---]*
end of 1:1-Block address contact other
Contact for Scientific Queries
start of 1:1-Block address scientific-contact
- Klinik für Kardiologie und PneumologieKlinikum Esslingen
- Mr. Dr. med. Martin Faehling
- Hirschlandstr. 97
- 73730 Esslingen
- Germany
end of 1:1-Block address scientific-contact

start of 1:1-Block address contact scientific-contact
- Telephone: 0711310382411
- Fax: [---]*
- E-mail: m.faehling at klinikum-esslingen.de
- URL: [---]*
end of 1:1-Block address contact scientific-contact
Contact for Public Queries
start of 1:1-Block address public-contact
- Klinik für Kardiologie und PneumologieKlinikum Esslingen
- Mr. Dr. med. Martin Faehling
- Hirschlandstr. 97
- 73730 Esslingen
- Germany
end of 1:1-Block address public-contact

start of 1:1-Block address contact public-contact
- Telephone: 071131032402
- Fax: [---]*
- E-mail: m.faehling at klinikum-esslingen.de
- URL: [---]*
end of 1:1-Block address contact public-contact

end of 1:n-Block addresses

start of 1:n-Block material support

Sources of Monetary or Material Support

Institutional budget, no external funding (budget of sponsor/PI)
start of 1:1-Block address materialSupport
- Klinik für Kardiologie und Pneumologie, Klinikum Esslingen
- 73730 Esslingen
- Germany
end of 1:1-Block address materialSupport

start of 1:1-Block address contact materialSupport
- Telephone: [---]*
- Fax: [---]*
- E-mail: [---]*
- URL: [---]*
end of 1:1-Block address contact materialSupport

end of 1:n-Block material support

start of 1:1-Block state

Status

Recruitment Status: Recruiting ongoing
Study Closing (LPLV): [---]*

end of 1:1-Block state

start of 1:n-Block publications

Trial Publications, Results and other Documents

trial protocol (mandatory for transfer to Studybox): Prüfplan
trial protocol (mandatory for transfer to Studybox): Ablaufplan

end of 1:n-Block publications

* This entry means the parameter is not applicable or has not been set.